CAR123 T cell treatment of relapsed/refractory hematologic malignancies.
UHKT-CAR123-01
Phase 1 other active
Quick answer
CAR123 T cell treatment of relapsed/refractory hematologic malignancies. for Relapsed/refractory CD123+ hematological malignancies: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Lymphoblastic Leukemia. is a Phase 1 program (other) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- Relapsed/refractory CD123+ hematological malignancies: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Lymphoblastic Leukemia.
- Phase
- Phase 1
- Modality
- other
- Status
- active